Verona Long Term Debt from 2010 to 2025
| VRNA Stock | USD 66.78 0.03 0.04% |
Long Term Debt | First Reported 2018-03-31 | Previous Quarter 120 M | Current Value 120.3 M | Quarterly Volatility 39.1 M |
Check Verona Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verona Pharma's main balance sheet or income statement drivers, such as Interest Expense of 24.7 M, Selling General Administrative of 157.2 M or Other Operating Expenses of 206.8 M, as well as many indicators such as Price To Sales Ratio of 97.85, Dividend Yield of 0.0 or PTB Ratio of 19.44. Verona financial statements analysis is a perfect complement when working with Verona Pharma Valuation or Volatility modules.
Verona | Long Term Debt |
Latest Verona Pharma's Long Term Debt Growth Pattern
Below is the plot of the Long Term Debt of Verona Pharma PLC over the last few years. Long-term debt is a debt that Verona Pharma PLC has held for over one year. Long-term debt appears on Verona Pharma PLC balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Verona Pharma PLC balance sheet is the sum of the balances of all categories of long-term debt. It is debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years. Verona Pharma's Long Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verona Pharma's overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt | 10 Years Trend |
|
Long Term Debt |
| Timeline |
Verona Long Term Debt Regression Statistics
| Arithmetic Mean | 19,646,878 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 214.95 | |
| Mean Deviation | 29,516,552 | |
| Median | 0.00 | |
| Standard Deviation | 42,231,910 | |
| Sample Variance | 1783.5T | |
| Range | 126.4M | |
| R-Value | 0.69 | |
| Mean Square Error | 1012T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | 6,084,004 | |
| Total Sum of Squares | 26753T |
Verona Long Term Debt History
Other Fundumenentals of Verona Pharma PLC
About Verona Pharma Financial Statements
Verona Pharma stakeholders use historical fundamental indicators, such as Verona Pharma's Long Term Debt, to determine how well the company is positioned to perform in the future. Although Verona Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Verona Pharma's assets and liabilities are reflected in the revenues and expenses on Verona Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Verona Pharma PLC. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Long Term Debt | 120.3 M | 126.4 M | |
| Long Term Debt Total | 564.6 K | 592.9 K | |
| Short and Long Term Debt Total | 2.4 M | 2.2 M | |
| Long Term Debt To Capitalization | 0.01 | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Verona Pharma Correlation against competitors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.